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The epidermal growth factor receptor (EGFR) is frequently
overexpressed in cancer and is an important therapeutic target.
Aberrant expression and function of microRNAs have been
associated with tumorigenesis. Bioinformatic predictions sug-
gest that the human EGFR mRNA 3-untranslated region con-
tains threemicroRNA-7 (miR-7) target sites, which are not con-
served across mammals. We found that miR-7 down-regulates
EGFR mRNA and protein expression in cancer cell lines (lung,
breast, and glioblastoma) via two of the three sites, inducing cell
cycle arrest and cell death. Because miR-7 was shown to
decrease EGFRmRNA expression, we used microarray analysis
to identify additional mRNA targets of miR-7. These included
Raf1 and multiple other genes involved in EGFR signaling and
tumorigenesis. Furthermore, miR-7 attenuated activation of
protein kinase B (Akt) and extracellular signal-regulated kinase
1/2, two critical effectors of EGFR signaling, in different cancer
cell lines. These data establish an important role for miR-7 in
controlling mRNA expression and indicate that miR-7 has the
ability to coordinately regulate EGFR signaling in multiple
human cancer cell types.
The epidermal growth factor receptor (EGFR),4 a member of
the erbB receptor family, is widely expressed in human tissues
and regulates important cellular processes, including prolifera-
tion, differentiation, and development (1). EGFR overexpres-
sion occurs in a range of solid tumors and is associated with
disease progression, resistance to chemotherapy and radiation
therapy, and poor prognosis (2). Consequently, the EGFR and
its downstream signaling effectors are major targets for new
therapeutics such asmonoclonal antibodies and tyrosine kinase
inhibitors (3). However, the clinical responses of tumors to
existing anti-EGFR agents are often limited, and thus a major
research focus is the development of novel approaches to block
EGFR expression and signaling (4).
MicroRNAs (miRNAs) are short, endogenous, non-coding
RNA molecules that bind with imperfect complementarity to
the 3-untranslated regions (3-UTRs) of target mRNAs, caus-
ing translational repression of the target gene or degradation of
the target mRNA (5–7). miRNAs are involved in a range of
processes that includes development, differentiation (8), prolif-
eration, and apoptosis (9) and have been implicated in cancer
(10). Many miRNA genes are located at sites in the human
genome that are frequently amplified, deleted, or rearranged in
cancer (11), suggesting that some miRNAs may act as onco-
genes (“oncomirs” 12) or tumor suppressors (10). For instance,
reduced expression of the let-7 family of miRNAs is associated
with increased Ras oncogene expression and reduced survival
in patients with non-small cell lung cancer (NSCLC) (13, 14). In
contrast, increased expression of miR-21 in gliomas (15), and
breast, colon, lung, pancreas, prostate, and stomach cancers
(16) is associatedwith apoptosis resistance, reduced chemosen-
sitivity, and increased tumor growth (17).
Computational approaches tomiRNA target prediction have
used criteria such as sequence complementarity between target
mRNAs and a “seed” region within the miRNA, and conserva-
tion of predicted miRNA-binding sites across 3-UTRs from
multiple species (reviewed in Refs. 18, 19). Recently, additional
features that determine target site functionality have been iden-
tified (20). Nevertheless, the imperfect complementarity of
miRNA and target sequences means that identification and
functional validation of authentic miRNA targets remains a
major challenge. It has been suggested that miRNAs may have
the ability to regulate hundreds or even thousands of target
mRNAs (21) and thatmuch of this regulation could occur at the
level of mRNA decay (22). Because specific miRNAs have the
potential to regulate the expression of several members of a
signaling pathway or cellular process (23), we hypothesized a
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role for miRNAs in aberrant EGFR expression and signaling in
human cancers. In this study, we identify EGFR and Raf1 as
direct targets of miR-7 in cancer cells, with miR-7 blocking
EGFR and Raf1 expression by inducing mRNA decay. Further-
more, we demonstrate the potential for miR-7 to act as a tumor
suppressor by coordinately regulating the EGFR signaling path-
way at multiple levels to repress protein kinase B (Akt) and
extracellular signal-regulated kinase 1/2 (ERK1/2) activity in
human cancer cell lines.
EXPERIMENTAL PROCEDURES
Cell Culture, miRNA Precursors, and Normal Tissue RNA—
A549, MDA-MB-468, U87, DU145, and U373 cell lines were
obtained from the American Type Culture Collection (ATCC)
and cultured at 37 °C in 5% CO2 with Dulbecco’s modified
Eagle’smedium supplementedwith 10% fetal bovine serum and
1% penicillin/streptomycin. Synthetic miRNA precursor mole-
cules corresponding to humanmiR-7 (Pre-miRmiRNAPrecur-
sor Product ID: PM10047) and a negative controlmiRNA (miR-
NC; Pre-miR miRNA Precursor Negative Control #1, Product
ID: AM17110) were obtained from Ambion. Total RNA (First-
Choice) from normal brain, normal lung, and normal breast
tissue was purchased from Ambion.
Luciferase Plasmid Construction—pGL3-miR-7-target was
generated by ligating annealed DNA oligonucleotides corre-
sponding to the perfect hsa-miR-7 target site (forward: 5-CAA
CAA AAT CAC TAG TCT TCC A-3 and 5-TGG AAG ACT
AGT GAT TTT GTT G-3) to unique SpeI and ApaI sites that
were inserted 3 of the luciferase open reading frame of pGL3-
control (Promega) firefly luciferase reporter vector (designated
pGL3-control-MCS (24)). Full-length EGFR 3-UTR reporter
plasmid was synthesized by GenScript Corp. using the entire
EGFR 3-UTR (nt 3879–5616 of GenBankTM accession num-
ber NM_005228) and the pMIR-REPORT luciferase plasmid
backbone (Ambion). Wild-type (WT) EGFR target reporter
plasmids pGL3-EGFR-A, -B, and -C were generated by cloning
annealed oligonucleotides corresponding to nt 4214–4260, nt
4302–4348, and nt 4585–4631, respectively, of EGFR (Gen-
BankTM accession number NM_005228) mRNA 3-UTR into
SpeI and ApaI sites in pGL3-control-MCS. Plasmid pGL3-
EGFR-D contained a PCR-generated EGFR 3-UTR sequence
that spanned the predicted miR-7 target sites B and C. Mutant
(MT) reporters were also generated that included three nucle-
otide substitutions to impair binding of the miR-7 seed
sequence to its target. Plasmids pGL3-RAF1-WT and pGL3-
RAF1-MT were constructed by cloning annealed DNA oligo-
nucleotides corresponding to nt 2965–3030 of the Raf1mRNA
3-UTR (GenBankTM accession number NM_002880), into the
SpeI and ApaI sites in pGL3-control-MCS. The sequence of all
plasmids was confirmed by sequencing.
Transfections and Luciferase Assays—Cells were seeded 24 h
prior to transfection in 6-well plates or 10-cm dishes and trans-
fected using Lipofectamine 2000 (Invitrogen) withmiRNApre-
cursor molecules at final concentrations ranging from 0.1 to 30
nM. Cells were harvested at 12–24 h (for RNA extraction) or 3
days (for protein extraction). For reporter gene assays, cells
were seeded in 24-well plates and co-transfected using Lipo-
fectamine 2000 (Invitrogen) with 100 ng of firefly luciferase
reporterDNAand 5 ng of pRL-CMVRenilla luciferase reporter
DNA as a transfection control. Lysates were assayed for firefly
and Renilla luciferase activities 24 h after transfection using the
Dual Luciferase Report Assay System (Promega) and a Fluostar
OPTIMAmicroplate reader (BMGLabtech). Expression values
were normalized to Renilla luciferase.
RT-PCR—Total RNA was extracted from cell lines with
TRIzol reagent (Invitrogen) and RNeasy columns (Qiagen) and
treated with DNase I (Promega) to eliminate contaminating
genomicDNA. For qRT-PCR analysis ofEGFR andRaf1mRNA
expression, 1g of total RNAwas reverse transcribed to cDNA
with random hexamers and Thermoscript (Invitrogen). Real-
time PCR for Raf1 andGAPDHwas performed using a Corbett
3000 RotorGene instrument (Corbett Research) with Quanti-
Tect SYBR Green PCR mixture (Qiagen) with primers from
PrimerBank (25) (EGFR-F, 5-GCGTTCGGCACGGTGTAT
AA-3; EGFR-R, 5-GGC TTT CGG AGA TGT TGC TTC-3;
RAF1-F, 5-GCACTGTAGCACCAAAGTACC-3; RAF1-R,
5-CTG GGA CTC CAC TAT CAC CAA TA-3; GAPDH-F,
5-ATGGGGAAGGTGAAGGTCG-3;GAPDH-R, 5-GGG
GTC ATT GAT GGC AAC AAT A-3). Expression of EGFR
and Raf1 mRNA relative to GAPDH mRNA was determined
using the 2CT method (26).
For analysis of miR-7 expression by qRT-PCR, reverse tran-
scription and PCR were carried out using TaqMan miRNA
assay kits (Applied Biosystems) for hsa-miR-7 (Part #4373014)
and U44 snRNA (Part #4373384) with a Corbett 3000 Rotor-
Gene thermocycler (Corbett Research) according to the man-
ufacturer’s instructions. Statistical analyses of qRT-PCR data
were performed using GenEx software (MultiD).
Western Blotting—Cytoplasmic protein extracts were pre-
pared as described (24), resolved on NuPAGE 4–12% Bis-Tris
gels (Invitrogen), and transferred to polyvinylidene difluoride
membranes (RocheApplied Science).Membranes were probed
with anti-EGFR mouse monoclonal antibody (1:1,000, Neo-
markers, catalog #MS-400-P1), anti-Raf1 mouse monoclonal
antibody (1:1,000, Santa Cruz Biotechnology, sc-7267), anti-
IRS2 rabbit monoclonal antibody (1:500, Cell Signaling Tech-
nology, #4502), anti-Akt rabbit monoclonal antibody (1:1,000,
Cell Signaling Technology, #9272), anti-phospho-Akt
(Ser-473) rabbit monoclonal antibody (1:500, Cell Signaling
Technology, #4060), anti-p44/42 (ERK1/2) MAPK mouse
monoclonal antibody (1:750, Cell Signaling Technology,
#4696), anti-phospho-p44/42 (P-ERK1/2) MAPK (Thr-202/
Tyr-204) rabbit monoclonal antibody (1:750, Cell Signaling
Technology, #9101), or anti--actin mouse monoclonal anti-
body (1:15,000, Abcam ab6276–100), prior to detection with
ECL Plus detection reagent (GE Healthcare) and ECL-Hyper-
film (GE Healthcare).
Cell CycleAnalysis andCell Counting—Following trypsiniza-
tion, cells were permeabilized, stained with propidium iodide,
and analyzed on anEPICSXL-MCL (CoulterCorp. flow cytom-
eter). Cell cycle analysis was performed using MultiPlus AV
MultiParameter data analysis software (Phoenix FlowSystems).
Cells were seeded in 6-cm dishes and assessed 3 days after
miR-7 or miR-NC transfection by light microscopy. Five repre-
sentative fields of view were photographed for each condition.
Cells in each field of view were counted manually.
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Microarray Expression Profiling and Analysis—Total RNA
was isolated fromA549 cells transfected for 24 h with miR-7 or
miR-NC (30 nM) using TRIzol reagent (Invitrogen) and RNeasy
columns (Qiagen) and assessed for quality and integrity using a
2100Bioanalyzer (Agilent Technologies). Gene expression pro-
filing by microarray hybridization was performed with two
experimental replicates by the Lotterywest State Microarray
Facility using Human Genome U133 Plus 2.0 array chips
(Affymetrix). The raw data were processed using GeneSifter
software (VizX Labs). An “all groups must pass” restriction was
imposed, with a threshold quality score of “P” (present)
required for inclusion in subsequent analysis. Data were nor-
malized to the all means fluorescence and were log2-trans-
formed. Pairwise analysis of the probe intensities of miR-7- and
miR-NC-treated sample data sets was performed using Stu-
dent’s t tests (two-tailed, unpaired), and used to identify tran-
scripts that were significantly up-regulated or down-regulated
with miR-7 transfection (p  0.05) by at least a factor of 2.
These represented potential miR-7 target transcripts.
Investigation of the enrichment of gene sets for predicted
miRNA targets was conducted using the L2L microarray anal-
ysis tool (27). miRanda (28), PicTar (29), and TargetScan (21)
were used for miR-7 target predictions. Analysis of the enrich-
ment of gene sets for functional Kyoto Encyclopedia of Genes
and Genomes (KEGG) pathways was performed with Gene-
Sifter software (VizX Labs). Microarray expression data have
been deposited in the Gene Expression Omnibus under Acces-
sion Number GSE14507.
RESULTS
EGFR 3-UTR Contains Multiple, Specific Target Sequences
for miR-7—As EGFR expression is regulated in part via cis-
acting 3-UTR mRNA stability sequences (30), we sought to
identify miRNAs that could regulate EGFR gene expression in
human cells. TargetScan (21) identified three putative miR-7
target sites (A, B, and C, Fig. 1A). The 3-end of each site con-
tains the hexamermotif UCUUCC, which is complementary to
the seed region (nt 2–7) of humanmiR-7 (hsa-miR-7) (Fig. 1B).
When contextual features of miRNA target sites associated
with functionality were taken into account, such as their prox-
imity to AU-rich sequences and positioning away from the cen-
ter of 3-UTRs (20), EGFR sites B and C ranked in the top 6%
and 4%, respectively, of all predicted miR-7 target sites in
TargetScan. Target site A ranked only in the top 56% of
TargetScan predicted sites for miR-7. This suggested that sites
B and C were more likely to represent functional targets of
miR-7 than site A. The miRanda algorithm (28) also predicted
EGFR to be a miR-7 target, whereas PicTar (29) did not.
Although miR-7 is normally expressed in the brain, lens, pitui-
tary, and hypothalamus (31–33), its expression is significantly
decreased in pituitary adenomas and in a panel of central nerv-
ous system cancer cell lines relative to normal tissue (34, 35).
This raises the possibility that it may function as a tumor sup-
pressor in these systems by inhibiting oncogene expression.
The three putative EGFR 3-UTR miR-7 target sites are poorly
conserved between human, mouse, and rat (Fig. 1B). Binding
sites that are not conserved between species are often excluded
in an attempt to reduce the number of false-positives in target
prediction sets. However, the evolution of miRNAs and their
target mRNAs suggests that this exclusion could also increase
the rate of false-negative predictions (19). For instance, inmice,
miR-7b regulates Fos oncogene translation via a 3-UTR target
site that is not present in human FosmRNA (36).
To investigate the interaction between miR-7 and its pre-
dicted EGFRmRNA3-UTR target sites, we generated reporter
vectors containing sequences with complementarity to miR-7
downstream of a luciferase open reading frame (Fig. 1C). These
included a sequence with perfect complementarity to the
miR-7 sequence (miR-7 target), the full-length wild-type EGFR
3-UTR (EGFR 3-UTR), four wild-type EGFR 3-UTR
sequences (A–D), and the same four EGFR sequences with
three point mutations predicted to disrupt miR-7 binding in
each of the seed match regions (Fig. 1D). In human EGFR-
overexpressing NSCLC cells (A549) transfected with synthetic
miR-7 precursor (miR-7), expression of the perfect target
reporter was reduced, an effect that was not observed following
transfection with a negative control miRNA precursor (miR-
NC) (Fig. 1E). Similarly, miR-7, but not miR-NC, reduced
expression of a reporter that contained the full-length EGFR
3-UTR (Fig. 1E).
We next investigated the relative contribution of each puta-
tive miR-7 target site in the EGFR 3-UTR to the regulation of
gene expression by miR-7. In A549 cells, miR-7 reduced the
expression of reporters bearing putative target sites B and C,
but not of the correspondingmutant reporters (Fig. 1F). In con-
trast, putative target site A did notmediate a change in reporter
expression by miR-7 (Fig. 1F). This suggested that site A alone
was not a target for miR-7 binding. The presence of sites B and
C in the same reporter construct (plasmid construct EGFR D,
Fig. 1C), conferred additive, although not synergistic, repres-
sion with miR-7, which was not observed with the EGFR D
mutant reporter (Fig. 1F). Together, these data indicate that the
EGFR 3-UTR is a specific target of miR-7 and that two of the
three predicted miR-7-binding sites in the EGFR mRNA
3-UTR are likely to be specific targets of miR-7. Furthermore,
these data suggest that miR-7may repress EGFR expression via
target sites B and C in an additive fashion.
miR-7 Inhibits EGFR Expression in Human Cancer Cell Lines
and Has Reduced Expression in U87 Glioblastoma Cells—We
next sought to determine the effect of miR-7 on EGFR mRNA
and protein expression in EGFR-positive A549, U87 (glioblas-
toma), MDA-MB-468 (breast cancer), and DU145 (prostate
cancer) cell lines. Compared with transfection with miR-NC
precursor, transfection with miR-7 precursor reduced EGFR
mRNA expression significantly in A549, U87, MDA-MB-468,
and DU145 cells at 24 h post-transfection by qRT-PCR (Fig.
2A), consistent with miR-7 promoting EGFRmRNA decay. On
the other hand, Lee and co-workers (36) observed that miR-7
regulated translation ofFosmRNA in themouse hypothalamus.
These contrasting results suggest that miR-7 may regulate the
stability and/or translation of target mRNAs. Furthermore,
compared with transfection with either transfection reagent
alone or miR-NC, transfection with miR-7 for 72 h reduced
EGFR protein expression in A549, U87, MDA-MB-468, and
DU145 cells, shown by immunoblotting (Fig. 2B). This effect
was observed with concentrations of miR-7 precursor as low as
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FIGURE 1. Identification of two specificmiR-7 target sites within the non-conserved EGFRmRNA 3-UTR. A, schematic representation of the EGFRmRNA
with three 3-UTR miR-7 binding sites (A, B, and C) predicted by TargetScan. B, sequence alignment of predicted EGFR 3-UTR miR-7 target sites showing lack
of conservation between human, mouse, and rat. The miR-7 seed target sequence (UCUUCC) is shown in bold and underlined, and conserved nucleotides are
shaded. Stars indicate nucleotides conserved across all five species. C, schematic representation of firefly luciferase reporter constructs for consensus miR-7
target, full-length wild-type EGFR 3-UTR, and truncated EGFR 3-UTR (A–D) miR-7 target sites. D, sequence of wild type (WT) and mutant (MT) EGFR mRNA
3-UTR miR-7 target sites. Mutations predicted to disrupt miRNA-mRNA binding were made in the seed target region. E, luciferase reporter assay to verify
activity of miR-7 upon the consensus miR-7 target site and full-length wild-type EGFR 3-UTR. A549 cells were transfected with consensus miR-7 target or
full-length wild-type EGFR 3-UTR firefly luciferase plasmid and either miR-7 or miR-NC precursor. Relative luciferase expression (firefly normalized to Renilla)
values are expressed as a ratio of reporter vector alone (S.D.). Data are representative of at least three independent experiments. *, a significant difference
from vehicle (Lipofectamine 2000)-treated reporter vector (p 0.001). F, luciferase reporter assay with A549 cells that were transfected with WT or MT EGFR
target site (A, B, C, orD) 3-UTR firefly-luciferase reporter, control Renilla-luciferase, and eithermiR-7 ormiR-NC precursor. Relative luciferase expression (firefly
normalized to Renilla) values are the ratio of miR-7-treated reporter vector compared with the same miR-NC-treated reporter vector (S.D.). Data are repre-
sentative of at least three independent experiments. *, a significant difference frommiR-NC-transfected controls (p 0.05).
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1 nM (data not shown). In addition to investigations of the reg-
ulation of EGFR expression by miR-7 in cancer cells, we
examined the expression of miR-7 in two EGFR-positive glio-
blastoma cell lines (U87 and U373) using TaqMan miRNA
qRT-PCRassays.Weobserved that the expression ofmiR-7was
significantly down-regulated in U87 and U373 cells compared
with RNA extracted from total normal human brain tissue (Fig.
2C). This result is consistent with the possibility that reduced
miR-7 levels could be associated with elevated expression of
EGFR in primary cerebral tumors. We also compared expres-
sion of miR-7 in normal brain, normal lung, and normal breast,
to its expression in A549, MDA-MB-468, and DU145 cell lines
(Fig. 2C and supplemental Fig. 1),
and found very low expression of
miR-7 in the normal lung and breast
compared with normal brain, sug-
gesting that miR-7 expression is
restricted to specific tissues that
include those belonging to the cen-
tral nervous system. Supporting this
finding, we observed thatmiR-7was
expressed at low levels in A549,
MDA-MB-468, and DU145 cells
compared with normal brain.
Functional Effects of miR-7 in
EGFR-positive Human Cancer Cell
Lines—Based on our data showing
that miR-7 can regulate EGFR
expression in cancer cells, we
hypothesized that miR-7 might
compromise the growth and viabil-
ity of the same cells. To test this
hypothesis, we transfected A549
cells withmiR-7 ormiR-NC precur-
sors and measured cell cycle pro-
gression using propidium iodide
staining and flow cytometry, and
cell numbers using cell counts at 3
days post-transfection. Transfec-
tion with miR-7 induced cell cycle
arrest at G1 (Fig. 3A) and caused a
significant decrease in A549 cell
numbers and cell viability (Fig. 3B).
The reduction in viable cell num-
ber with miR-7 transfection did
not appear to involve apoptosis, as
evidenced by, firstly, the absence
of a sub-G1 cell population by pro-
pidium iodide staining and flow
cytometry (Fig. 3A) and, secondly,
the lack of activation of the execu-
tioner caspases 3 and 7 (data not
shown). Thus, our results suggest
that miR-7 not only inhibits EGFR
gene expression by targeting its
mRNA for degradation but in-
duces a program of gene expres-
sion to reduce cell viability and
trigger non-apoptotic cell death.
In view of the important role of EGFR in the protein kinase B
(Akt) and extracellular signal-regulated kinase 1/2 (ERK1/2)
signaling pathways, two pathways linked to cancer, we exam-
ined the ability of miR-7 transfection to repress Akt and
ERK1/2 activity in different cancer cell lines. Following trans-
fection of A549, U87,MDA-MB-468, andDU145 cell lines with
miR-7, we observed reductions in basal and EGF-induced phos-
phorylation ofAkt (Fig. 3,C andD, and supplemental Fig. 2A) in
all four cell lines. The capacity of miR-7 to regulate ERK1/2
activity appeared to be cell-specific, because miR-7 decreased
EGF-stimulated ERK1/2 phosphorylation in U87 cells but did
FIGURE 2.miR-7 regulates EGFR expression in cancer cell lines and is down-regulated in glioblastoma
cell lines. A, quantitative RT-PCR analysis of EGFR mRNA expression in A549, U87, MDA-MB-468, and DU145
cells 24 h after transfection with miR-7 or miR-NC precursor. EGFR RNA expression was normalized to GAPDH
RNA expression and is shown as a ratio of miR-NC-transfected cells (S.D.) using the 2CT method. Data are
representative of three independent experiments. *, a significant difference frommiR-NC-transfected control
cells (p  0.003). B, immunoblotting detection of EGFR and -actin expression using 15 g of cytoplasmic
protein extracts harvested fromA549, U87,MDA-MD-468, andDU145 cells 3 days after transfectionwithmiR-7
ormiR-NC. C, quantitative RT-PCR analysis ofmiR-7 expression in U87 andU373 glioblastoma cells, and normal
lung and A549 cells, compared with normal total brain RNA. 10 ng of total RNA was reverse-transcribed, and
miR-7 expressionwas determined by TaqManmiRNA qRT-PCR assay. miR-7 expressionwas normalized to U44
snRNA expression, and miR-7 expression was calculated (S.D.) relative to normal total brain RNA using the
2CT method. Data are representative of three independent experiments. *, a significant difference from
normal total brain RNA (p 0.0001).
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not alter ERK1/2 phosphorylation in A549, MDA-MB-468, or
DU145 cells (Fig. 3, E and F, and supplemental Fig. 2B).
Together, these observations are consistentwithmiR-7’s ability
to inhibit cancer cell cycle progression and reduce cell viability,
and suggest that, in addition to the regulation of EGFR expres-
sion, miR-7 can regulate the activity of important downstream
signaling effectors of EGFR, including Akt and ERK1/2, in mul-
tiple EGFR-positive cancer cell lines.
miR-7 Regulates the Expression of Raf1 andOtherMembers of
EGFR Signaling Pathways—miRNAs can have multiple and
sometimes functionally related targets (23). We performed
microarray analysis using RNA from A549 cells transfected
with miR-7 or miR-NC to identify additional genes and biolog-
ical pathways that could be regulated by miR-7 (Fig. 4A; A549/
miR-7 versus A549/miR-NC). Because EGFR mRNA expres-
sion was reduced by miR-7 via two specific 3-UTR target sites
(Fig. 2A), it was likely that additional mRNA targets of miR-7
could be identified through a microarray approach.
Microarrays with RNA extracted
from miR-7- and miR-NC-trans-
fected A549 cells were performed,
with two experimental replicates for
each condition. Analysis of the
resulting data indicated that 248
transcripts were significantly down-
regulated by 2-fold in the miR-7-
transfected cells relative to themiR-
NC-transfected cells, whereas 199
transcripts were significantly up-
regulated by2-fold (p 0.05) (Fig.
4A and supplemental Table S1). The
set of down-regulated transcripts
was of particular interest, given its
potential to contain miR-7 targets.
We used the L2L analysis tool (27)
(see “Experimental Procedures”) to
investigate whether there was
enrichment of the set of down-reg-
ulated transcripts for predicted
miR-7 targets. This analysis showed
that the set of down-regulated tran-
scripts was significantly enriched by
2.18-fold (p 0.025) with predicted
targets of miR-7, but not of any
other known miRNA. This enrich-
ment for predicted miR-7 target
genes validates our microarray
approach using a test employed by
other studies that has also been
usingmicroarray analysis to identify
direct and indirect targets of
miRNA action (37).
The proportion of miR-7 target
predictions present in the set of
down-regulated transcripts was dif-
ferent for the three algorithms used
(TargetScan, PicTar, and miRanda,
Fig. 4B). 32% (96/303) of Target-
Scan-predicted miR-7 targets, 7% (17/259) of PicTar-predicted
miR-7 targets, and 2% (19/1070) of miRanda-predicted miR-7
targets were down-regulated in our miR-7 microarray at the
mRNA level. Similarly, 39% (96/248) of miR-7-down-regulated
transcripts were predicted by TargetScan, and 8% were pre-
dicted by PicTar and miRanda (17/248 and 19/248, respec-
tively). These differences likely reflect the different approaches
of the three programs to target site prediction, whereby
miRanda predicted a total of 1070 miR-7 target mRNAs,
TargetScan predicted 303 target mRNAs, and PicTar predicted
259 target mRNAs. Of the 248 transcripts significantly down-
regulated by miR-7, 9 were predicted by the combination of
both miRanda and PicTar, 16 were predicted by both miRanda
and TargetScan, and 17 were predicted by both PicTar and
TargetScan. Furthermore, nine of the transcripts down-regu-
lated in response tomiR-7were predicted by all three programs
to be miR-7 targets: Raf1, PSME3, PSME3, PLEC1, CKAP4,
CNOT8, CNN3, CAPZA1, PFN2, and ARF4. These nine genes
FIGURE 3.miR-7 alters cancer cell cycle progression and cell viability via regulation of Akt and ERK1/2
signaling pathways. A, cell cycle analysis using propidium iodide staining and flow cytometry of A549 cells
that had been transfected with miR-7 or miR-NC for 3 days. Cell cycle profile data for the three A549 cell
populations (control, miR-7 precursor, miR-NC precursor) are shown from a representative experiment (n 3).
B, microscopic assessment of viability of A549 cells 3 days after transfection with miR-7 or miR-NC by light
microscopy (40magnification). Bars represent mean percentage difference in cell counts (S.D.) compared
with vehicle (Lipofectamine 2000) only. *, a significant difference from LF2000 control (p 0.001). C, immuno-
blottingdetectionof P-Akt andAkt expression inA549 cells that hadbeen transfectedwithmiR-7ormiR-NC for
3 days and treated with PBS or EGF (10 ng/ml for 15 min). D, immunoblotting detection of P-Akt and Akt
expression in U87 cells that had been transfectedwithmiR-7 ormiR-NC for 3 days and treatedwith PBS or EGF
(10 ng/ml for 15 min). E, immunoblotting detection of P-ERK1/2 and ERK1/2 expression in A549 cells that had
been transfected with miR-7 or miR-NC for 3 days and treated with PBS or EGF (10 ng/ml for 15 min).
F, immunoblotting detection of P-ERK1/2 and ERK1/2 expression in U87 cells that had been transfected with
miR-7 or miR-NC for 3 days and treated with PBS or EGF (10 ng/ml for 15 min).
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are of particular interest in view of a recent recommendation
that investigation of candidate miRNA targets should be prior-
itized based on their prediction by two or three of these pro-
grams (38).
Of these genes, Raf1, whose mRNA expression was signifi-
cantly down-regulated by 3.47-fold by miR-7 in the microarray
experiment (p  0.02), was of interest to us because of the
known involvement of Raf1 protein in the EGFR signaling path-
way. Raf1 is a downstream effector of EGFR signaling in the
Raf-MEK-ERK cascade that is commonly activated by muta-
tions and/or overexpressed in human cancers (39).We hypoth-
esized that miR-7may coordinately regulate multiple members
of the EGFR signal transduction pathway. To confirm the Raf1
microarray result, we performed qRT-PCR on RNA fromA549
cells transfected with miR-7 or miR-NC. This showed down-
regulation of the expression of Raf1mRNA relative toGAPDH
mRNA with miR-7 (Fig. 5A), suggesting that miR-7 promotes
decay of Raf1 mRNA. TargetScan predicted that the human
Raf1 3-UTR contains two miR-7 target sites (Fig. 5B). To
determinewhethermiR-7 can directly regulate Raf1 expression
in cancer cells, reporter assay experiments were conducted
with A549 cells. In these experiments, miR-7 reduced the
expression of a reporter construct that carried both of the pre-
dicted miR-7 target sites from the Raf1 3-UTR but not of a
reporter containing an analogous insert with three point muta-
tions in each seed match region (Fig. 5C). This indicated that
the Raf1mRNA 3-UTR is a specific target of miR-7 in cancer
cells. Raf1 protein expression was also reduced in A549 and
MDA-MB-468 cells transfected with miR-7 compared with
untransfected cells and to cells transfected with miR-NC (Fig.
5D). Together, these data provide evidence that, via direct bind-
ing to its 3-UTR, miR-7 regulates the expression of Raf1, a
downstream effector of EGFR signaling in the Raf-MEK-ERK
cascade.
To further investigate the possible functional roles of miR-7,
we performed an analysis on the microarray data to identify
KEGG pathways that were significantly enriched with genes
that were down-regulated in response to miR-7 (Fig. 6A). The
“ErbB signaling pathway,” “GnRH signaling pathway,” “gli-
oma,” “long term potentiation,” and “gap junction” pathways
were all found to be significantly enriched (supplemental Figs.
S3–S7). These results support a role formiR-7 in the regulation
of erbB signaling. They are also in line with the expression pro-
file of miR-7, which is brain-specific with the highest expres-
sion in the pituitary and hypothalamus, and with the down-
regulation of miR-7 in central nervous system tumors,
including pituitary tumors (34, 35). In addition to EGFR and
Raf1, several other down-regulated genes from these pathways
contain predicted binding sites for miR-7. These include genes
involved in calcium signaling (CALM3 and CAMK2D, down-
regulated 7.10- and 2.08-fold, p 0.006 and p 0.024, respec-
tively), cytoskeleton reorganization and nuclear signaling
(PAK1, down-regulated 2.20-fold, p  0.006), and cAMP syn-
thesis and intracellular signaling (ADCY9, down-regulated
3.38-fold, p  0.005) (supplemental Table S1). This suggests
that miR-7 has the ability to target multiple cell signaling path-
ways by coordinately regulating the expression of key signaling
molecules.
DISCUSSION
We have demonstrated that miR-7 can regulate the expres-
sion of multiple effectors of EGFR signaling. As well as directly
targeting EGFR andRaf1, miR-7 down-regulates the expression
of a number of other genes associated with cellular pathways
downstream of EGFR. Furthermore, miR-7 has functional
effects in cancer cell lines that include inducing cell cycle arrest
and reducing cell growth and viability.
EGFR as a Target ofmiR-7 in Cancer Cells—Amajor obstacle
to the understanding of miRNA signaling and function has
been the shortage of validated miRNA targets. This is due in
part to the likely ability of a given miRNA to regulate the
expression of hundreds or even thousands of target mRNAs,
but also to the imperfect complementarity ofmiRNAand target
sequences. Recent work has revealed some of the criteria that
support an authentic miRNA-mRNA interaction. We chose to
investigate the predicted interaction between miR-7 and the
EGFR mRNA 3-UTR, which does not satisfy one of the com-
monly used criteria for miRNA-target prediction, that is, con-
servation of the miRNA binding site(s) across species. Our rea-
soning was based on the evolution of regulatory sequences with
increasing species complexity.
Although EGFR overexpression in many cancers often
occurs via gene amplification, a subset of tumors with EGFR
overexpression does not exhibit EGFR gene amplification. In
FIGURE 4. Identification of candidatemiR-7 target mRNAs bymicroarray
analysis of miR-7 transfected A549 cells. A, scatterplot showing log inten-
sities of miR-7-transfected A549 cells (y axis) plotted against the log intensi-
ties of miR-NC-transfected cells (x axis). Differentially expressed genes are
colored in red (more highly expressed in miR-7-transfected cells) or green
(more highly expressed in miR-NC-transfected cells). B, intersection of pre-
dictedmiR-7 target lists (from TargetScan, PicTar, andmiRanda) with the 248
transcripts significantly down-regulated by miR-7 in A549 cells.
Regulation of EGFR Signaling in Cancer bymiR-7
FEBRUARY 27, 2009•VOLUME 284•NUMBER 9 JOURNAL OF BIOLOGICAL CHEMISTRY 5737
 at UQ Library on October 9, 2016
http://w
w
w
.jbc.org/
D
ow
nloaded from
 
one study, it was found that	20% of the EGFR-overexpressing
glioblastomas tested lacked EGFR gene amplification (40), sug-
gesting that other, possibly post-transcriptional, mechanisms
exist to promote aberrant EGFR expression in cancer cells. We
have identified miR-7 as a regulator of EGFR gene expression
and signaling in human cancer cells. Furthermore, the normal
expression of miR-7 in the brain and endocrine systems,
together with the previously reported down-regulation of
miR-7 in central nervous system tumors, suggests that miR-7
has the ability to act as a regulator of normal cellular pathways
in some systems and as an endogenous tumor suppressor in
others.
miR-7 and the Regulation of EGFR Signaling Pathways in
Normal andCancer Cells—Our results show thatmiR-7 has the
ability to coordinately down-regulate the expression of multi-
plemembers of EGFR signaling cascades, both directly, as is the
case for EGFR and Raf1, and indirectly, and also to induce can-
cer cell cycle arrest and cell death. Our data further suggest that
miR-7 may have several tissue-specific functions, with possible
roles in the development and progression of gliomas, reproduc-
tion, via the production of pituitary gonadotropins, and learn-
ing and memory, through regulation of many other signaling
and structural proteins in addition to EGFR and Raf1 (Fig. 6B).
A number of recent reports support a role for miR-7 in the
brain and in tumor cells. miR-7 has been shown in one study to
belong to a subset of miRNAs that are down-regulated in schiz-
ophrenia (43). Interestingly, the predicted targets of the dis-
regulated miRNAs in the study, like the mRNAs down-regu-
lated bymiR-7 in the present study, are over-represented in the
KEGG functional pathways of “focal adhesion,” “regulation of
actin cytoskeleton,” and “gap junction” (Fig. 6A), and may ulti-
mately influence synaptic plasticity in schizophrenia.
With respect to systems involving EGFR signaling, the
MAPK ERK5 is regulated by miR-143 in differentiated adipo-
FIGURE 5.miR-7 regulates Raf1 expression via specific binding to the Raf1mRNA3-UTR. A, qRT-PCR analysis of Raf1 expression in A549 cells transfected
with miR-7 or miR-NC for 24 h. Raf1 expression was normalized to GAPDH expression and data shown relative to miR-NC-transfected cells using the 2CT
method (meanS.D.,n3). *, a significantdifference frommiR-NCcontrol (p0.0005).B, schematic representationofRaf1mRNA3-UTR showingconserved
(C) and non-conserved (NC) predicted seed target sites formiR-7 binding.C, luciferase reporter gene assay usingA549 cells thatwere transfectedwith Raf1-WT
or Raf1-MT firefly luciferase reporter plasmid DNA, Renilla luciferase plasmid DNA, and either miR-7 or miR-NC, for 24 h. Firefly expression was normalized to
Renilla expression. Data are expressed as a ratio of miR-NC-transfected A549 cells (S.D.). Results are representative of those obtained from at least three
independent experiments. **, a significant difference from Raf1WT/miR-NC (p 0.05). D, immunoblotting detection of Raf1 and -actin expression using 15
g of cytoplasmic protein extracts harvested from A549 and MDA-MB-468 cells 3 days after transfection with miR-7 or miR-NC.
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cytes and cancer cell lines (41, 42) in much the same way as
miR-7 regulates the ERK1/2 pathway, suggesting that miRNAs
such asmiR-7 andmiR-143have the ability to regulate signaling
effectors critical to cell growth and differentiation. Two other
reports implicate miR-7 in the regulation of EGFR signaling. In
one, miR-7 was shown to control EGFR signaling inDrosophila
photoreceptor cells (44). This study presented a model in
which, upon cell differentiation, EGFR signaling triggers ERK-
mediated degradation of the transcription repressor Yan,
thereby relieving Yan-mediated repression of miR-7 expres-
sion. Conversely, miR-7 represses Yan expression in photore-
ceptors via binding to Yan 3-UTR sequences. This feedback
loop thus promotes mutually exclusive expression of Yan and
miR-7.However, EGFR is unlikely to represent a direct target of
miR-7 inDrosophila due to the lack of conservation of theDro-
sophilamiR-7 target sites to humans.
While this report was in preparation, a recent report byKefas
and coworkers demonstrated thatmiR-7 inhibits EGFR expres-
sion and the Akt pathway in glioblastomas, tumors shown to
have reduced miR-7 expression relative to normal brain tissue
(45). The regulation of insulin receptor substrate 2 (IRS2) expres-
sionwas proposed as amechanism to explain howmiR-7 controls
Akt activity.Wehave confirmed the regulation of IRS2 expression
at the protein level by miR-7 in the other cell lines used in our
experiments (supplemental Fig. S8).Wedid not note a decrease in
IRS2 mRNA expression in miR-7-transfected A549 cells in our
microarray experiments. Similarly, for eachof the cell lines used in
this study, we did not observe a significant difference in IRS2
mRNA expression between cells transfected with miR-7 and
miR-NC by qRT-PCR (data not shown), suggesting that miR-7
regulates IRS2 expression at the translational level.
There are a number of key differences between the study by
Kefas and coworkers and the present study. Firstly, we evalu-
ated the relative contribution of each of the three predicted
miR-7 target sites in the EGFR 3-UTR to the regulation of gene
expression by miR-7, show that two of the three predicted
miR-7 target sites are directly targeted by miR-7, and demon-
strate the specificity of these interactions through mutational
analysis of the target site seed regions. Secondly, we observed a
reduction in EGFRmRNA with miR-7 transfection in multiple
EGFR-positive cell lines, using qRT-PCR and microarray anal-
ysis, whereas Kefas and coworkers reported no change in EGFR
mRNA expression with miR-7 transfection. Our finding
enabled the use of microarray analysis of miR-7-transfected
cells. Thirdly, we did not observe the classicmarkers of apopto-
tic cell death with miR-7 transfection, i.e. we did not detect a
substantial sub-G1 apoptotic peak or activation of caspases 3 or
7 in miR-7-transfected cells. Fourthly, in addition to a role in
the regulation of Akt signaling, our findings implicate miR-7
in the regulation of ERK1/2 signaling in cancer cells, at least in
part via its ability to regulate the expression of Raf1 kinase.
Furthermore, the regulation of these signaling effectors by
miR-7 is shown to occur in a range of EGFR-positive cancer cell
line models.
Finally, we have extended our investigation beyond the iden-
tification of EGFR as a target of miR-7 to explore additional
cellular pathways in which miR-7 may be involved, using
microarray analysis of miR-7-transfected cancer cells. This
analysis has linked miR-7 to a number of pathways relevant to
normal and tumor cells. Furthermore, this analysis suggested
several other miR-7 target candidates that are linked to EGFR
signaling, including MEK, PI3K, Akt, CAMK, PAK1, and ARF4
(Fig. 6B). The reduced expression of both PI3K and Akt mRNA
by miR-7 in our array is interesting. However, in our studies,
miR-7 did not significantly alter total Akt protein expression,
whereas it did alter Akt phosphorylation. Similarly, the down-
FIGURE 6. Identification of functional pathways enriched withmiR-7 tar-
get genes. A, table of KEGG pathways significantly enriched (z-score  2)
with genes down-regulated by miR-7 compared with miR-NC in A549 cells.
B, schematic model showing coordinate regulation of EGFR signaling by
miR-7 via multiple targets. Direct, validated target mRNAs of miR-7 include
EGFR and Raf1 (dark circles). Gray circles represent EGFR signaling genes with
expression modulated by treatment with miR-7 by unknownmechanism.
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regulation of MAP2K2 (MEK) expression in the microarray
suggests that miR-7 could potentially regulate ERK1/2 activity
at a third point in the cascade, in addition to its regulation of
EGFR and Raf1.
ADP-ribosylation factor 4 (ARF4) is another interesting
miR-7 target candidate gene that was down-regulated in the
microarray results. The ARF4 protein interacts with EGFR and
mediates EGF-dependent activation of the transcription factor
AP-1 (46). Therefore, by regulating ARF4 expression, miR-7
could potentially alter a broad program of gene expression
through control of EGF-dependent AP-1 activity. Another
miR-7-regulated gene, calmodulin kinase II (CAMK2), has
important roles in the central nervous system relating to long
term potentiation and neurotransmitter release (47). This may
be significant given that miR-7 is known to be abundantly
expressed in the hypothalamus and pituitary, major sites for
neurotransmitter secretion. p21/Cdc42/Rac1-activated kinase
1 (PAK1) is a serine/threonine kinase that mediates several
oncogenic signaling pathways, including EGFR/Akt signaling,
to regulate cytoskeletal remodeling, cell motility, cell prolifera-
tion, and apoptosis (reviewed in Ref. 48). PAK1 was down-reg-
ulated by miR-7 in our microarray studies and was a predicted
target of miR-7. PAK1 expression is increased in some cancers; in
glioblastoma patients its elevated expression is associated with
shorter survival time (49).Recently,PAK1was showntobea target
of miR-7 in cancer cells (50), suggesting that the reduced expres-
sion ofmiR-7 in glioblastomasmight promote the aberrant PAK1
expression and activity seen in these tumors.
The benefit of abrogating EGFR expression in a variety of
human cancer types as a therapeutic approach has been empha-
sized by recent data showing that the kinase-independent func-
tion of EGFR is to prevent autophagic cell death bymaintaining
the basal intracellular glucose level through an interaction with
the sodium/glucose co-transporter 1 (51). To date, clinical tri-
als of EGFR tyrosine kinase inhibitors in a variety of cancers
have yielded disappointing results. Co-inhibition of kinase-in-
dependent and kinase-dependent EGFR functions could
achieve durable clinical responses. Agents such as miR-7 that
down-regulate expression of the EGFR as well as some of its
signaling effectorsmay have significant therapeutic potential in
a range of human cancer types.
In summary, our data indicate that miR-7 coordinately reg-
ulates EGFR signaling at multiple levels and suggest that miR-7
additionally regulates a number of other cellular pathways rel-
evant to normal and tumor cells. The effect ofmiR-7 action is to
inhibit cell cycle progression and reduce cell growth and viabil-
ity. The reported down-regulation of miR-7 in tumors of the
central nervous system, together with its ability to regulate
oncogenic EGFR signaling in multiple cancer cell line models,
suggests that the therapeutic up-regulation of miR-7 expres-
sion in these tumors may inhibit growth and metastasis.
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Supplementary Fig. 1, Quantitative RT-PCR analysis of miR-7 expression in normal breast, MDAMB- 
468 and DU145 cells compared to normal total brain RNA. 10 ng of total RNA was 
reversetranscribed and miR-7 expression determined by TaqMan miRNA qRT-PCR assay. miR-7 
expression was normalized to U44 snRNA expression and miR-7 expression was calculated (±SD) 
relative to normal total brain RNA using the 2-__C T method. Data are representative of three 
independent experiments. 
 
Supplementary Fig. 2. A. Immunoblotting detection of P-Akt and Akt expression in MDA-MB-468 and 
DU145 cells that had been transfected with miR-7 or miR-NC for 3 d and treated with PBS or EGF 
(10 ng/ml for 15 min). B. Immunoblotting detection of P-ERK1/2 and ERK1/2 expression in MDA-MB-
468 and DU145 cells that had been transfected with miR-7 or miR-NC for 3 d and treated with PBS 
or EGF (10 ng/ml for 15 min). 
 
Supplementary Fig. 3, 4, 5, 6 & 7. Functional KEGG pathways significantly enriched (z-score > 2) for 
genes downregulated by miR-7 in A549 cells compared to miR-NC. These include “glioma” 
(Supplementary Fig. 3), “ErbB signaling pathway” (Supplementary Fig. 4), “GnRH signaling pathway” 
(Supplementary Fig. 5), “long-term potentiation” (Supplementary Fig. 6), “gap junction” 
(Supplementary Fig. 7). Genes marked with asterisks are those with established roles in these 
pathways that were also significantly downregulated by miR-7 in microarray analysis. 
 
Supplementary Fig. 8. B. Immunoblotting detection of IRS2 and _-actin expression using 15 ⎧g of 
cytoplasmic protein extracts harvested from A549, MDA-MB-468 and DU145 cells 3 d after 
transfection with miR-7 or miR-NC. 
 
Supplementary Table 1. All genes whose expression is downregulated by more than 2-fold at 24 h in 
A549 cells transfected with miR-7 compared to miR-NC. The number of predicted miR-7 target sites 
for each gene according to TargetScan, PicTar and miRanda is shown. 
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